Does BMI affect the effectiveness of DMPA contraceptive injection?
Notes about answers
This service falls under our Trip Learning Environment (Triple) concept: A supportive, learning and nurturing space where we encourage users to share their knowledge and experience.
If you see something you feel is wrong, don’t criticise (that misses the point of Triple) courteously and supportively give a counter answer.
Answers given should be in good faith, but they should not be considered definitive, be critical.
We do not endorse or verify content posted by users.
Thanks for your response,
Thanks for your question,
- Responded 30 May 2019 · The Faculty of Sexual and Reproductive Healthcare have a guideline ‘Overweight, Obesity and Contraception’ (https://www.fsrh.org/standards-and-guidance/documents/fsrh-clinical-guideline-overweight-obesity-and-contraception/1overweight-obesity-and-contraception-guideline-april-2019.pdf) where they report: The available evidence suggests that effectiveness of depot medroxyprogesterone acetate (DMPA) is not affected by body weight or BMI. From the limited evidence available it is not possible to confirm or exclude a causal association between DMPA use and venous thromboembolism (VTE). Whilst obesity alone does not restrict the use of DMPA (UKMEC 1), DMPA use becomes a UKMEC 3 when obesity is one of multiple risk factors for cardiovascular disease (e.g. smoking, diabetes and hypertension). DMPA use appears to be associated with some weight gain, particularly in women under 18 years of age with a BMI ≥30 kg/m2. Conflict of interest declaration: None
- Answer this question